指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

孟加拉国内分泌学会(BES)关于COVID-19患者糖尿病及其他内分泌疾病管理的立场声明

Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19.
指南 / 共识 · Diabetes Metab Syndr Obes · 2021-05-18
一句话结论孟加拉国内分泌学会(BES)建议COVID-19合并糖尿病患者HbA1c目标<7.0%(部分临床情况可放宽),必须避免低血糖(<3.9 mmol/l),重症患者需频繁监测血糖。

该立场声明由孟加拉国内分泌学会制定,针对COVID-19合并糖尿病及其他内分泌疾病患者,提出适用于初级和专科诊疗的实用建议。声明指出糖尿病患者COVID-19致死风险可比非糖尿病者高至多50%,合并糖尿病与COVID-19者病死率(CFR)为7.3–9.2%,而无合并症者为0.9–1.4%。糖尿病酮症酸中毒可能是COVID-19死亡原因之一,患者血糖波动大,可能与饮食不规律、运动减少、糖皮质激素分泌增加及使用糖皮质激素有关。声明强调多数患者HbA1c目标<7.0%但可适当放宽,更重视日常血糖水平,必须避免低血糖(<3.9 mmol/l),重症患者需频繁监测血糖。

要点

  • 糖尿病患者COVID-19致死风险可比非糖尿病者高至多50%;合并糖尿病与COVID-19者CFR 7.3–9.2%,无合并症者0.9–1.4%。
  • 糖尿病酮症酸中毒可能是COVID-19死亡原因之一,需警惕。
  • COVID-19糖尿病患者血糖波动大,可能与饮食不规律、运动减少、糖皮质激素分泌增加及使用糖皮质激素有关。
  • 多数患者HbA1c目标<7.0%,适当临床情况可放宽;更重视日常血糖水平,必须避免低血糖(<3.9 mmol/l)。
  • 重症患者需频繁监测血糖。

适用人群与场景

  • COVID-19合并糖尿病或其他内分泌疾病或任何其他合并症的患者,适用于初级和专科诊疗场景。
  • 重点关注老年人和有合并症等脆弱人群。

诊断标准与关键阈值

  • HbA1c目标:多数患者<7.0%,适当临床情况可放宽。
  • 低血糖阈值:血糖<3.9 mmol/l必须避免。

处置流程与药物剂量

  • 更重视日常血糖水平而非仅HbA1c。
  • 重症患者需频繁监测血糖。

红旗征与不能漏的情况

  • 糖尿病酮症酸中毒可能是COVID-19死亡原因之一,需警惕。

研究设计与关键结果

  • 制定机构:孟加拉国内分泌学会(Bangladesh Endocrine Society)。
  • 方法:形成适用于初级和专科诊疗的实用建议。

证据类型、等级与局限

  • 证据类型:立场声明(指南/共识)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对COVID-19合并糖尿病患者,应设定个体化HbA1c目标(多数<7.0%,适当临床情况可放宽),并重点管理日常血糖、避免低血糖(<3.9 mmol/l)。
  • 重症患者需频繁监测血糖。

指南或共识出处

  • 孟加拉国内分泌学会(Bangladesh Endocrine Society)立场声明,发表于Diabetes Metab Syndr Obes。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The year 2020 witnessed a largely unprecedented pandemic of coronavirus disease (COVID-19), caused by SARS COV-2. Many people with COVID-19 have comorbidities, including diabetes, hypertension and cardiovascular diseases, which are significantly associated with worse outcomes. Moreover, COVID-19 itself is allied with deteriorating hyperglycemia. Therefore, Bangladesh Endocrine Society has formulated some practical recommendations for management of diabetes and other endocrine diseases in patients with COVID-19 for use in both primary and specialist care settings.

OBJECTIVE: The objective of the article is to develop a guideline to protect the vulnerable group with utmost preference - the elderly and those with comorbid conditions. Therefore, to ensure the adequate protective measures and timely treatment for COVID-19 patients with diabetes, other endocrine diseases or any other comorbidities.

CONSIDERING AND MONITORING ISSUES: The risk of a fatal outcome from COVID-19 may be up to 50% higher in patients with diabetes than in non-diabetics.Patients with diabetes and COVID had CFR 7.3-9.2%, compared with 0.9-1.4% in patients without comorbidities.Diabetic ketoacidosis may be one of the causes of mortality in COVID-19.There is wide fluctuation of blood glucose in these patients, probably due to irregular diet, reduced exercise, increased glucocorticoids secretion, and use of glucocorticoids. HbA1c should be <7.0% for the majority of the patients, this target may be relaxed in appropriate clinical settings.More emphasis should be given on day-to-day blood glucose levels. Hypoglycemia (<3.9 mmol/l) must be avoided.Frequent monitoring of blood glucose is needed in critically ill patients.

CONCLUSION: The fight against COVID-19 has been proven to be a challenging one. Therefore, all healthcare personnel should make the best use of updated knowledge and skills to ensure adequate protective measures and timely treatment for COVID-19 patients with diabetes, other endocrine diseases or any other comorbidities.

来源:Diabetes Metab Syndr Obes,查看原文。版权归原作者所有。

参考来源

  1. Pathan F, Selim S, Fariduddin M, et al. Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19. Diabetes Metab Syndr Obes. 2021. PMID: 34040407. doi:10.2147/DMSO.S293688

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。